Additional Advances in Extrapulmonary Neuroendocrine Carcinomas

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies that present unique diagnostic and therapeutic challenges. While treatment has historically followed small cell lung cancer (SCLC) pathways, the rapid emergence of Delta-like ligand 3 (DLL3)–targeted therapies—particularly bispecific T-cell engagers—is poised to reshape the treatment landscape. In this discussion, Dr. Danielle Hutchings and Dr. Andrew Hendifar sit down to explore the critical importance of accurate pathologic classification, the biological rationale behind targeting DLL3, ongoing clinical trial updates, and the practical challenges surrounding immunohistochemistry (IHC) testing thresholds in routine practice. Read the full accompanying article on Oncology Data Advisor: oncdata.com/additional-advances-ep-necs What You’ll Learn in This Episode: ● Pathologic Classification: Why distinguishing well-differentiated neuroendocrine tumors (NETs) from poorly differentiated neuroendocrine carcinomas (NECs) is essential for selecting correct treatment algorithms. ● Targeting DLL3 in EP-NECs: How DLL3-directed T-cell engager therapies recruit T cells to attack tumor cells, and why lower heterogeneity in EP-NECs may yield impressive treatment responses. ● Unresolved IHC Testing Thresholds: The ongoing debate surrounding optimal DLL3 positivity cutoffs (e.g., 1% vs. 50% vs. 75%) and overcoming send-out testing logistics. ● Expanding Clinical Trials: Future outlook for single-agent T-cell engagers and chemotherapy combinations in both first-line and refractory settings. ● Multidisciplinary Coordination: Why close communication between pathologists, medical oncologists, and radiologists is vital for navigating rare neuroendocrine neoplasms. Chapter Timestamps: 00:00 – Introduction: Unmet Needs in Extrapulmonary Neuroendocrine Carcinomas 01:20 – Pathologic Precision: NETs vs.